IL1B and inflammatory bowel disease: Similarly, anti-IL-1β were also thought to ameliorate the symptoms of inflammatory bowel diseases, Crohn’s disease, and ulcerative colitis, and to attenuate the development of non-small cell lung cell (NSCLC) in smokers [9,10].